Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc's, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically ...
AstraZeneca and Merck , known as MSD outside of the United States and Canada, today announced long-term results from the OlympiA Phase 3 trial which showed LYNPARZA (olaparib) demonstrated sustained, ...